The Search for a Safer Anesthetic
The story of ketamine begins in the early 1960s at Parke-Davis Laboratories in Detroit, Michigan. At the time, the pharmaceutical company was searching for a replacement for phencyclidine (PCP), an anesthetic that, while effective, produced severe and prolonged psychotomimetic side effects — hallucinations, agitation, and delirium — that made it impractical for widespread clinical use.
In 1962, organic chemist Calvin Stevens synthesized a new compound, CI-581, that would later be named ketamine. The compound was structurally related to PCP but had a shorter duration of action and fewer adverse psychological effects, making it a far more practical candidate for clinical anesthesia.
First Human Trials
The first human trials of ketamine took place in 1964 at the Jackson Prison in Michigan, under the direction of Dr. Edward Domino and Dr. Guenter Corssen. Volunteer prisoners received intravenous injections of the new compound, and the researchers observed a unique state they described as "dissociative anesthesia" — the patients appeared disconnected from their environment while maintaining certain reflexes and stable vital signs.
Dr. Domino's wife, Toni, is credited with suggesting the term "dissociative anesthetic" to describe the unusual state ketamine produced. The term has remained in use ever since and defines an entire class of drugs.
FDA Approval and the Vietnam War
Ketamine received FDA approval in 1970 under the brand name Ketalar. Its approval came at a pivotal moment in history. The Vietnam War was escalating, and military physicians urgently needed an anesthetic that could be safely administered in battlefield conditions — without the need for complex monitoring equipment or supplemental oxygen.
Ketamine proved ideal for this purpose. It maintained blood pressure and spontaneous breathing, did not require intravenous access in all cases (it could be given intramuscularly), and had a wide margin of safety. It became one of the most commonly used anesthetics on the battlefield and saved countless lives during the conflict.
Widespread Adoption in Medicine
Throughout the 1970s and 1980s, ketamine became a staple in several medical specialties:
- Pediatric anesthesia — Children tolerated ketamine well, and it became a first-line agent for procedural sedation in pediatric emergency departments.
- Emergency medicine — Its hemodynamic stability made it valuable for trauma patients and those in shock.
- Developing world — Ketamine's room-temperature stability, low cost, and safety profile made it the anesthetic of choice in resource-limited settings. The World Health Organization added it to its List of Essential Medicines.
- Veterinary medicine — Ketamine became one of the most widely used veterinary anesthetics globally.
The Recreational Diversion
Beginning in the 1980s and accelerating through the 1990s, ketamine emerged as a recreational drug in nightclub and rave culture. Used at sub-anesthetic doses, it produced euphoria, visual hallucinations, and dissociative states that attracted recreational users. This led to growing concerns about diversion and abuse.
In 1999, the U.S. Drug Enforcement Administration (DEA) classified ketamine as a Schedule III controlled substance, imposing stricter regulations on its manufacture, distribution, and prescribing. Despite this scheduling, ketamine remained legally available for medical use and continued to be widely used in clinical settings.
The Psychiatric Discovery
The most transformative chapter in ketamine's history began in 2000 when Dr. John Krystal and colleagues at Yale University published a landmark study in the journal Biological Psychiatry. The study demonstrated that a single, low-dose intravenous infusion of ketamine (0.5 mg/kg over 40 minutes) produced rapid and significant antidepressant effects in patients with major depressive disorder.
This finding was revolutionary for several reasons. First, the effects were visible within hours — an unprecedented speed compared to the weeks required by conventional antidepressants. Second, the study suggested an entirely new neurobiological model of depression centered on the glutamate system rather than the monoamine hypothesis that had dominated psychiatry for decades.
The 2006 NIMH Study
In 2006, researchers at the National Institute of Mental Health (NIMH), led by Dr. Carlos Zarate, published a pivotal study in the Archives of General Psychiatry. This double-blind, placebo-controlled trial confirmed ketamine's rapid antidepressant effects in treatment-resistant depression. Within 24 hours of a single infusion, 71% of patients met criteria for response and 29% achieved full remission.
This study galvanized the psychiatric research community and launched an era of intense investigation into glutamate-based treatments for mood disorders.
FDA Approval of Esketamine
In March 2019, the FDA approved esketamine (Spravato), a nasal spray containing the S-enantiomer of ketamine, for treatment-resistant depression. It was approved under a Risk Evaluation and Mitigation Strategy (REMS), meaning it must be administered in certified healthcare settings where patients are monitored for at least two hours after each dose.
In August 2020, the FDA expanded Spravato's indication to include major depressive disorder with acute suicidal ideation or behavior — making it one of the first medications specifically approved for this urgent clinical scenario.
The Current Era
Today, ketamine occupies a unique position in medicine. It remains an essential anesthetic worldwide while simultaneously representing the most significant advance in psychiatric pharmacology in decades. Hundreds of specialized ketamine clinics have opened across the United States and internationally, offering IV infusions and other formulations for depression, PTSD, chronic pain, and other conditions.
Research continues at a rapid pace, with investigations into optimal dosing, long-term outcomes, combination approaches, novel delivery systems, and the therapeutic potential of the R-enantiomer (arketamine). The story of ketamine is far from over — it is, in many ways, just beginning its most important chapter.
References
- MedlinePlus: Ketamine Injection — National Library of Medicine drug information on ketamine's clinical uses and FDA-approved indications
- FDA: Drug Information — U.S. Food and Drug Administration center for drug evaluation, including ketamine and esketamine approval records
- MedlinePlus: Esketamine Nasal Spray — Drug information on FDA-approved Spravato (esketamine) for treatment-resistant depression
- WHO: Depression Fact Sheet — World Health Organization information on global depression burden and the WHO Essential Medicines list
Share